Edition:
United States

Summit Therapeutics PLC (SMMT.OQ)

SMMT.OQ on NASDAQ Stock Exchange Global Market

2.46USD
20 Jul 2018
Change (% chg)

-- (--)
Prev Close
$2.46
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
20,027
52-wk High
$16.59
52-wk Low
$2.17

Chart for

About

No overview information found for .
No analyst recommendations are available for .

Overall

No Ratios Available.

Financials

  SMMT.OQ Industry Sector
P/E (TTM): -- 217.69 33.34
EPS (TTM): -- -- --
ROI: -- -3.65 13.18
ROE: -- -5.62 15.09

Summit plunges 80 percent after muscle-wasting disorder drug fails

Britain's Summit Therapeutics Plc said on Wednesday that it would stop developing its Duchenne muscular dystrophy (DMD) drug after it failed a mid-stage study, wiping out nearly 80 percent of its market value.

Jun 27 2018

UPDATE 2-Summit plunges 80 pct after muscle-wasting disorder drug fails

* Plummets 80 pct to touch record low (Adds details on trial, analyst comment)

Jun 27 2018

Summit Therapeutics to stop developing muscle-wasting disorder drug

June 27 Summit Therapeutics Plc said on Wednesday that it would stop developing its Duchenne muscular dystrophy (DMD) drug after it failed to meet the goals of a mid-stage study.

Jun 27 2018

BRIEF-Summit Therapeutics Files For Mixed Shelf Of Upto $225 Million

* SUMMIT THERAPEUTICS PLC FILES FOR MIXED SHELF OF UPTO $225 MILLION - SEC FILING Source http://bit.ly/2jXftRN Further company coverage:

May 15 2018

BRIEF-Summit Therapeutics Says Proposed Placing To Raise Up To 15 Mln Stg

* ‍ANNOUNCES A PROPOSED PLACING TO RAISE UP TO £15.0 MILLION​

Mar 27 2018

BRIEF-Summit's Infectious Diseases Technology Platform Yields Novel Antibiotics With Potential In Global Fight Against Gonorrhoea

* SUMMIT’S INFECTIOUS DISEASES TECHNOLOGY PLATFORM YIELDS NOVEL ANTIBIOTICS WITH POTENTIAL IN GLOBAL FIGHT AGAINST GONORRHOEA

Mar 13 2018

BRIEF-Summit Expands Enrolment In Phaseout DMD Phase 2 Clinical Trial To Include Planned Additional Group

* SUMMIT EXPANDS ENROLMENT IN PHASEOUT DMD PHASE 2 CLINICAL TRIAL TO INCLUDE PLANNED ADDITIONAL GROUP Source text for Eikon: Further company coverage:

Mar 07 2018

BRIEF-Summit Therapeutics Says Muscle Damage Reduced After Treatment With Ezutromid

* EZUTROMID SIGNIFICANTLY REDUCED MUSCLE DAMAGE IN DMD PATIENTS IN 24-WEEK INTERIM DATA FROM SUMMIT’S PHASEOUT DMD CLINICAL TRIAL

Jan 25 2018

Earnings vs. Estimates

No consensus analysis data available.